The Ergomed team is looking forward to being part of the 16th Orphan Drugs & Rare Diseases Global Congress 2022 Europe in London on the 17th and 18th of February 2022.
We are pleased to mention that, Zizi Imatorbhebhe, ERGOMED Senior Vice President, Global Strategy and Development, Rare Disease, has been invited to join a keynote panel discussion about “Expectations and Future Directions For Gene Therapy”, and she will have a spotlight discussion with the topic “A strategic Framework to guide rare drug-disease development planning”.
This two-day Congress aims to provide the attendees with a comprehensive overview and discussion about the critical issues shaping the future of the industry of orphan drugs and rare diseases. For more information on the conference, please visit .
If planning to attend, please stop by the Ergomed table to meet our commercial team and our expert, who will be happy to answer any questions you might have and discuss how Ergomed solutions can best support your Orphan study.
ERGOMED Senior Vice President, Global Strategy and Development, Rare Disease,
Zizi is a seasoned executive with over 32+ years of drug development and commercial experience in the Bio-pharmaceutical, Clinical Research (CRO), and Healthcare industry. She has been instrumental in working collaboratively with many global sponsors especially in the Rare Disease space to identify drug development challenges for their programs and provide solutions to address them. She has also successfully commercialized over 25 pharmaceutical and medical device products globally. In addition, she works to leverage innovations to develop patient-oriented solutions and expand clinical trial access.
Keynote Panel Discussion
Panel Discussion Title: “Expectations and Future Directions For Gene Therapy”
Date and Time: Day 1 – Feb @ 12:30
Session Title: “A strategic Framework to guide rare drug-disease development planning”
Date and Time: Day 2 – Feb @ 12:00
- How is this advanced therapy fundamentally changing the way rare diseases patients are treated?
- Improving clinical development by new-age clinical trial design and recruitment
- An effective framework for developing the delivery system for the next generation of medicine
- Making manufacturing and commercialization viable
- Unconventional payment models to ensure innovative treatment can be accessed by rare disease patients
If attending, stop by our table and meet Prashant & Rada
Director, Business Development
Senior Director, Business Development
If you have any questions or want to set up a meeting with the Ergomed team during the event, you can reach Prashant and Rada directly or via email@example.com.
We look forward to seeing you there!